Baillie Gifford & Co. Sells 417,709 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Baillie Gifford & Co. lowered its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 3.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,345,887 shares of the company’s stock after selling 417,709 shares during the quarter. Baillie Gifford & Co. owned about 0.09% of Denali Therapeutics worth $388,766,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC lifted its stake in Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after buying an additional 1,847 shares during the period. CWM LLC increased its stake in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after acquiring an additional 654 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics during the 1st quarter valued at $88,000. Assetmark Inc. boosted its stake in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after acquiring an additional 580 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Denali Therapeutics in the first quarter worth $147,000. Institutional investors own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Citigroup upped their price target on Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Denali Therapeutics in a report on Thursday, November 7th. Wedbush decreased their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Finally, Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.90.

Denali Therapeutics Trading Up 0.7 %

DNLI stock opened at $31.58 on Tuesday. The company’s 50 day moving average is $27.95 and its 200 day moving average is $23.73. The stock has a market cap of $4.54 billion, a price-to-earnings ratio of -11.44 and a beta of 1.40. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period last year, the firm earned ($0.72) EPS. As a group, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.62 EPS for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now directly owns 29,096 shares of the company’s stock, valued at $844,656.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.